Related Experiment Videos
Strategy for purification of coagulation factor concentrates
D B Clark1, W N Drohan, S I Miekka
1American Red Cross, Jerome H. Holland Laboratory, Biomedical Sciences, Rockville, MD 20855.
Annals of Clinical and Laboratory Science
|May 1, 1989
Summary
Biotechnology advances are revolutionizing plasma fractionation, enhancing product purity, safety, and recovery. New technologies are enabling the development and purification of critical therapeutic proteins like factor IX and fibrin glue.
Area of Science:
- Biotechnology
- Biochemistry
- Protein Purification
Background:
- Traditional plasma fractionation methods have limitations in product purity and recovery.
- Advances in biotechnology offer opportunities to improve existing plasma-derived therapies.
- There is a continuous need for safer and more effective plasma-derived products.
Purpose of the Study:
- To describe the impact of biotechnology on plasma fractionation.
- To highlight improvements in product purity, safety, and recovery.
- To present applications of new technologies in purifying specific plasma proteins.
Main Methods:
- Application of advanced biotechnological techniques.
- Development of novel purification strategies.
- Focus on specific plasma-derived proteins and products.
Main Results:
- Significant improvements in product purity, safety, and recovery achieved.
- Development of new plasma-derived products is facilitated.
- Successful application of technology to purify factor IX, factor X, protein C, antithrombin III, thrombin, and fibrin glue.
Conclusions:
- Biotechnology is transforming plasma fractionation.
- Enhanced purity, safety, and recovery are key benefits.
- New therapeutic products can be developed and purified more effectively.